[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100651941","phase-2-postoperative-tizanidine-use-in-pelvic-reconstructive-surgery-a-pilot-study-100651941",false,"NCT07766837","Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot Study","TIPS","Inclusion Criteria:\n\n* female, age ≥18 and ≤89 years old\n\n  * any race\u002Fethnicity\n  * English and\u002For Spanish fluency\n  * undergoing apical suspension:\n\n    * sacrocolpopexy (laparoscopic or robotic)\n    * uterosacral ligament suspension (vaginal, laparoscopic, or robotic)\n    * sacrospinous ligament fixation\n    * iliococcygeus suspension\n  * surgery being performed at Hartford Hospital\n\nExclusion Criteria:\n\n* male\n\n  * age \\\u003C18 or ≥90 years old\n  * pregnant\n  * breastfeeding\n  * documented diagnosis of hypotension in EMR problem list, BP in office or at pre-op PAC (confirmed on repeat) to be systolic \\\u003C100 mm Hg and\u002For diastolic \\\u003C70 mm Hg\n  * known intolerance or sensitivity to tizanidine\n  * current use of:\n\n    * CYP1A2 inhibitor:\n    * clonidine (alpha-2 agonist) antihypertensive\n    * opioid\n    * muscle relaxant\n  * pre-existing\n\n    * hepatic impairment as defined as transaminitis with ALT or AST \\>2x upper limit of normal\n    * diagnoses of cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD)\n    * renal impairment as defined by creatinine clearance \\\u003C25 mL\u002Fmin\n  * obstructive sleep apnea\n  * non-English or non-Spanish speaking\n  * past opioid dependence\n  * concurrent diagnosis of malignancy\n  * concurrent surgery apart from pelvic reconstructive surgery with another specialty\n  * unable\u002Funwilling to consent to participate","FEMALE","18 Years","89 Years",{"count":20,"type":21},186,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate whether adding tizanidine to the standard postoperative pain regimen improves recovery after pelvic reconstructive surgery in adult women. The main questions it aims to answer are:\n\nDoes postoperative tizanidine improve patient-reported recovery 4-6 weeks after surgery? Does tizanidine reduce postoperative pain, opioid use, constipation, and healthcare utilization while improving functional recovery?\n\nResearchers will compare standard postoperative care plus tizanidine with standard postoperative care alone to determine whether tizanidine improves postoperative recovery.\n\nParticipants will:\n\n* Be randomly assigned to receive either standard postoperative pain management alone or standard postoperative pain management plus tizanidine for 2 weeks after surgery.\n* Complete electronic surveys before surgery, 1-2 days after surgery, 2 weeks after surgery, and 4-6 weeks after surgery to assess pain, recovery, activity, and bowel function.\n* Allow researchers to review information from their electronic medical record, including healthcare utilization and postoperative outcomes, during the 4-6 weeks following surgery.",[27,28,29],"Post Operative","Post Operative Analgesia","Urogynecologic Surgery",[31,32,33],"post operative","tizanidine","urogynecology","NOT_YET_RECRUITING","2026-08-11",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":21},"2026-07-29",{"date":42,"type":21},"2028-07-29",{"name":44,"class":45},"Hartford Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100523847","comparing-use-of-incentive-spirometry-with-and-without-reminder-100523847","NCT06101030","Comparing Use of Incentive Spirometry With and Without Reminder","Comparing Post Operative Utilization of Incentive Spirometry With and Without Electronic Patient Reminder","Inclusion Criteria:\n\nPatients must meet all the following Inclusion criteria to be eligible for participation in the study:\n\n* Patient has undergone a qualifying surgical procedure.\n* Patient is aged 18 years or over.\n* Patient has incentive spirometry ordered or incentive spirometry must be part of the study site's standard of care which is implemented by hospital staff.\n* Patient is able to comply with all study required incentive spirometry instructions.\n* Patient is without severe hearing or impaired visual acuity deficiency such that they cannot hear or see the audible and visual signal for the InSee monitor.\n\nExclusion Criteria:\n\n* Patients meeting any of the following exclusion criteria at baseline will be excluded from study participation:\n\n  * Vulnerable Populations (Pregnant, minors, prisoners, those with significantly reduced mental acuity).\n  * Patients where incentive spirometry is inappropriate (patients with Tractotomy, patients who are hemodynamically unstable, patients in reverse isolation due to infection).\n  * Patients with a history of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction), or cognitive issue which would in the opinion of the investigator, make it difficult for the patient to comply with the study procedures or follow the investigators instructions.\n  * Any medical condition that, in the opinion of the investigator, would place the patient at increased risk if they participated.\n  * Any Physician determination that the patient should not participate.","ALL",{"count":55,"type":21},500,"OBSERVATIONAL","This study is designed to determine if patients using an incentive spirometer with visual and auditory signals will increase their use of the incentive spirometer and prevent lung complications.",[27],[60,27,61],"Incentive spirometry","compliance","RECRUITING","2025-04-07",{"date":65,"type":38},"2025-04-10",{"date":67,"type":38},"2024-01-16",{"date":69,"type":21},"2025-09-07",{"name":71,"class":72},"Tidal Medical Technologies","INDUSTRY",3]